ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis

Medicine (Baltimore). 2023 Sep 8;102(36):e35013. doi: 10.1097/MD.0000000000035013.

Abstract

The aim of this paper was to reveal the correlation between the expression of ELOVL fatty acid elongase 6 (ELOVL6) gene in lung adenocarcinoma (LUAD) and its clinical significance, immune cell infiltration level and prognosis. Expression profile data of ELOVL6 mRNA were collected from the cancer genome atlas database to analyze the differences in ELOVL6 mRNA expression in LUAD tissues and normal lung tissues, and to analyze the correlation between ELOVL6 and information on clinicopathological features. Based on TIMER database, TISDIB database and GEPIA2 database, the correlation between ELOVL6 expression and tumor immune cell infiltration in LUAD was analyzed. Gene ontology and Kyoto encyclopedia of genes and genomes enrichment analyses of ELOVL6-related co-expressed genes were performed to identify the involved signaling pathways and to construct their co-expressed gene protein interaction networks. Drugs affected by ELOVL6 expression were screened based on the Cell Miner database. These findings suggest that ELOVL6 plays an important role in the course of LUAD, and the expression level of this gene has a close relationship with clinicopathological characteristics and survival prognosis, and has the potential to become a prognostic marker and therapeutic target for LUAD.

MeSH terms

  • Adenocarcinoma of Lung* / genetics
  • Adenocarcinoma* / genetics
  • Computational Biology
  • Fatty Acid Elongases* / genetics
  • Humans
  • Immunosuppression Therapy
  • Lung Neoplasms* / genetics

Substances

  • ELOVL6 protein, human
  • Fatty Acid Elongases